Vericel Corp (VCEL):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C5154)
◆英語タイトル:Vericel Corp (VCEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5154
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年9月
◆ページ数:41
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. The company is also developing ixmyelocel-T technology, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. The company sells its products through cell therapy specialists. Vericel is headquartered in Cambridge, the US.

Vericel Corp (VCEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vericel Corp, Medical Devices Deals, 2012 to YTD 2018 9
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vericel Corp, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 11
Equity Offering 12
Vericel Raises USD74.8 Million in Public Offering of Shares 12
Vericel Raises USD19.6 Million in Public Offering of Shares 14
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Acquisition 20
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 20
Vericel Corp – Key Competitors 21
Vericel Corp – Key Employees 22
Vericel Corp – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 06, 2018: Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance 24
May 08, 2018: Vericel Reports First Quarter 2018 Financial Results 26
Mar 05, 2018: Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance 28
Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 30
Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 31
May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 33
Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 35
Corporate Communications 37
Aug 20, 2018: Vericel names Jonathan Hopper as chief medical officer 37
Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 38
Product Approvals 39
Feb 21, 2017: Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy 39
Other Significant Developments 40
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Vericel Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Vericel Corp, Medical Devices Deals, 2012 to YTD 2018 9
Vericel Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 11
Vericel Raises USD74.8 Million in Public Offering of Shares 12
Vericel Raises USD19.6 Million in Public Offering of Shares 14
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 15
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 16
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 18
Aastrom Biosciences Completes Private Placement Of Series B Convertible Preference Stock For US$40 Million 19
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 20
Vericel Corp, Key Competitors 21
Vericel Corp, Key Employees 22
Vericel Corp, Other Locations 23
Vericel Corp, Subsidiaries 23

List of Figures
Vericel Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vericel Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vericel Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vericel Corp, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Vericel Corp (VCEL):製薬・医療:M&Aディール及び事業提携情報(Vericel Corp (VCEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆